Ryan P. Smith, MD

  • Clinical Professor, Radiation Oncology
  • Co-Residency Program Director, Radiation Oncology, UPMC CancerCenter
  • Medical Director of Radiation Oncology at UPMC St. Margaret

I am the clinical medical director of the radiation oncology department at UPMC St. Margaret, with an academic appointment as clinical professor in the University of Pittsburgh medical school. Though I see patients with all types of cancer, I have a special interest in head and neck cancers and prostate cancer, with research interests in these sites, with a concentration in prostate brachytherapy.

Teaching Activities:

Assistant co-director of the radiation oncology residency program at UPMC, preceptor to radiation oncology residents as well as multiple medical students

Representative Publications

Benoit RM, Smith RP, Beriwal S.  Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy.  Clin Oncol (R Coll Radiol). 2014 Dec;26(12):776-80.. Epub 2014 Sep 15.  PMID: 25213299

Ling D, Vargo JA, Smith RP.  Radiation-induced esophageal strictures in a patient with CREST syndrome.   Practical Radiation Oncology.  2015:5-2

Champ CE, Francis L, Clement, RJ, Dickerman R, Smith RP. Fortifying the Treatment of Prostate Cancer with Physical Activity.  Prostate Cancer.  2016; 2016 PMID:  26977321.

Smith RP, Beriwal S, Benoit RM.  Long Term Rectal Toxicity and Rectal Bleeding Following Cs-131 Prostate Brachytherapy.  Submitted for publication

Champ CE, Smith RP.   Images in clinical medicine.  Radiation recall and woody fibrosis.   N Engl J. Med 2015 May 14; 372(20).  PMID: 25970071

Research Grants

Research grants and/or contract activity:

Academic grant (along with Dr. Ronald Benoit and Dr. Sushil Beriwal) through Isoray, Inc of $150,000 to conduct research in prostate brachytherapy

 

Summary of research:

We have ongoing projects looking at various aspects of prostate brachytherapy, with special attention to the use of the Cs-131 isotope and its comparison to I-125.   We have published many manuscripts on dosimetry, toxicity and 5 year outcomes of Cs-131 brachytherapy.

In addition, we have an investigator initiated protocol studying focal brachytherapy using Cs-131 for patients with low risk prostate cancer. 

I am co-PI on a study assessing activity levels in cancer patients.